scholarly journals 196 Hypofractionated Radiotherapy for Soft Tissue Sarcomas - Early Experience With 35GY in 5 Fractions

2019 ◽  
Vol 139 ◽  
pp. S82
Author(s):  
Mariana P. Araujo ◽  
Carolyn R. Freeman ◽  
Fabio L. Cury
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Early Experience ◽  
Hypofractionated Radiotherapy

scholarly journals Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas

Cancer ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2432-2439 ◽  
Author(s):  
Christopher W. Ryan ◽  
Anthony G. Montag ◽  
Janet R. Hosenpud ◽  
Brian Samuels ◽  
James B. Hayden ◽  
...  
Keyword(s):  
High Risk ◽  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Hypofractionated Radiotherapy ◽  
Histologic Response

scholarly journals Neoadjuvant Hypofractionated Radiotherapy and Chemotherapy in High-Grade Extremity Soft Tissue Sarcomas: Phase 2 Clinical Trial Protocol

2017 ◽  
Vol 6 (5) ◽  
pp. e97 ◽  
Author(s):  
Ranyell MSB Spencer ◽  
Samuel Aguiar Junior ◽  
Fabio O Ferreira ◽  
Paulo R Stevanato Filho ◽  
Bruna EC Kupper ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Hypofractionated Radiotherapy ◽  
High Grade ◽  
Trial Protocol ◽  
Phase 2 ◽  
Clinical Trial Protocol ◽  
Phase 2 Clinical Trial

Neoadjuvant Hypofractionated Radiotherapy and Chemotherapy for Extremity Soft Tissue Sarcomas: Safety, Feasibility, and Early Oncologic Outcomes of a Phase 2 Trial

2021 ◽  
Author(s):  
Maria Leticia Gobo Silva ◽  
Celso Abdon Lopes de Mello ◽  
Samuel Aguiar ◽  
Felipe D́Almeida Costa ◽  
Paulo Roberto Stevanato Filho ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Oncologic Outcomes ◽  
Hypofractionated Radiotherapy ◽  
Phase 2 ◽  
Phase 2 Trial

Preoperative hypofractionated radiotherapy in the treatment of localized soft tissue sarcomas

2014 ◽  
Vol 40 (12) ◽  
pp. 1641-1647 ◽  
Author(s):  
H. Koseła-Paterczyk ◽  
M. Szacht ◽  
T. Morysiński ◽  
I. Ługowska ◽  
W. Dziewirski ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Hypofractionated Radiotherapy

scholarly journals Hypofractionated preoperative radiotherapy for high risk soft tissue sarcomas in a geriatric patient population

2021 ◽  
Vol 55 (4) ◽  
pp. 459-466
Author(s):  
Vlatko Potkrajcic ◽  
Frank Traub ◽  
Barbara Hermes ◽  
Marcus Scharpf ◽  
Jonas Kolbenschlag ◽  
...  
Keyword(s):  
Wound Healing ◽  
High Risk ◽  
Soft Tissue ◽  
Geriatric Patient ◽  
Patient Population ◽  
Soft Tissue Sarcomas ◽  
Thoracic Wall ◽  
Hypofractionated Radiotherapy ◽  
Published Data ◽  
Specific Patient

Abstract Background Standard therapy for localised, resectable high risk soft tissue sarcomas consists of wide excision and radiotherapy over several weeks. This treatment schedule is hardly feasible in geriatric and frail patients. In order not to withhold radiotherapy from these patients, hypofractionated radiotherapy with 25 Gy in 5 fractions was evaluated in a geriatric patient population. Patients and methods A retrospective analysis was performed of 18 geriatric patients with resectable high risk soft tissue sarcomas of extremities and thoracic wall. Wound healing and short term oncologic outcome were analysed. In addition, dose constraints for radiotherapy of the extremities were transferred from normofractionated to hypofractionated radiotherapy regimens. Results Feasibility was good with 17/18 patients completing treatment as planned. Wound healing complication rate was in the range of published data. Two patients developed local and distant recurrence, two patients isolated distant recurrences. No isolated local recurrences were observed. Keeping the constraints was possible in all cases without compromising the coverage of the target volume. Conclusions Hypofractionated radiotherapy and surgery was well tolerated even in this specific patient population. With feasibility concerning early wound healing problems and adapted constraints, which allow for the treatment of most resectable extremity tumours, the concept warrants further evaluation in patients unfit for standard radiotherapy.

scholarly journals The Feasibility Study of Hypofractionated Radiotherapy with Regional Hyperthermia in Soft Tissue Sarcomas

Cancers ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1332
Author(s):  
Mateusz Jacek Spałek ◽  
Aneta Maria Borkowska ◽  
Maria Telejko ◽  
Michał Wągrodzki ◽  
Daria Niebyłowska ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Soft Tissue ◽  
Local Recurrence ◽  
Neoadjuvant Chemotherapy ◽  
Locally Advanced ◽  
Treatment Protocol ◽  
Soft Tissue Sarcomas ◽  
Distant Metastases ◽  
Hypofractionated Radiotherapy ◽  
Regional Hyperthermia

Introduction: Management of marginally resectable or unresectable soft tissue sarcomas (STS) in patients who are not candidates for neoadjuvant chemotherapy due to chemoresistant pathology or contraindications remains a challenge. Therefore, in these indications, we aimed to investigate a feasibility of 10x 3.25 Gy radiotherapy combined with regional hyperthermia (HT) that could be followed by surgery or 4x 4 Gy radiotherapy with HT. Materials and methods: We recruited patients with locally advanced marginally resectable or unresectable STS who (1) presented chemoresistant STS subtype, or (2) progressed after neoadjuvant chemotherapy, or (3) were unfit for chemotherapy. The primary endpoint was the feasibility of the proposed regimen. Results: Thirty patients were enrolled. All patients received the first part of the treatment, namely radiotherapy with HT. Among them, 14 received the second part of radiotherapy with HT whereas 13 patients underwent surgery. Three patients did not complete the treatment protocol. The feasibility criteria were fulfilled in 90% of patients. Two patients developed distant metastases. One patient died due to distant progression. One patient developed rapid local recurrence after surgery. Conclusions: Hypofractionated radiotherapy with HT is a feasible treatment for marginally resectable or unresectable STS in patients who are not candidates for chemotherapy. Results of this clinical trial support the further validation of RT and HT combinations in STS.

Sign in / Sign up

Export Citation Format

Share Document